8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 27, 2026·SEC
Material company update
Feb 24, 2026·SEC
TransMedics Group, Inc.(TMDX)Earnings, Financials & Key Ratios
TMDX•NASDAQ
16.2× P/E·Price updated Jun 19, 2026
AboutTransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Show more
- Revenue$605M+37.1%
- EBITDA$136M+137.1%
- Net Income$190M+436.6%
- EPS (Diluted)4.87+382.2%
- Gross Margin59.92%+0.9%
- EBITDA Margin22.42%+72.9%
- Operating Margin17.93%+111.2%
- Net Margin31.43%+291.3%
- ROE54.24%+179.7%
TMDX Key Insights
TransMedics Group, Inc. (TMDX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 22.1% free cash flow margin
- ✓Strong 5Y sales CAGR of 88.2%
- ✓Good 3Y average ROE of 19.4%
✗Weaknesses
- ✗Weak momentum: RS Rating 13 (bottom 13%)
- ✗Shares diluted 15.1% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TMDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TMDX Price & Volume
TransMedics Group, Inc. (TMDX) stock price & volume — 10-year historical chart
Loading chart...
TMDX Growth Metrics
TransMedics Group, Inc. (TMDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years88.21%
3 Years86.42%
TTM30.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM251.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM221.32%
Return on Capital
10 Years-28.43%
5 Years-7.38%
3 Years3.88%
Last Year12.6%
TMDX Recent Earnings
TransMedics Group, Inc. (TMDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.30-51.6%
$0.62
Rev
$174M-0.3%
$174M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.57+39.0%
$0.41
Rev
$161M+3.5%
$155M
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$0.66+78.4%
$0.37
Rev
$144M-7.5%
$155M
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$0.92+91.7%
$0.48
Rev
$157M+11.1%
$142M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.30vs $0.62-51.6% | $174Mvs $174M-0.3% |
| Q1 2026 | Feb 24, 2026 | $0.57vs $0.41+39.0% | $161Mvs $155M+3.5% |
| Q4 2025 | Oct 29, 2025 | $0.66vs $0.37+78.4% | $144Mvs $155M-7.5% |
| Q3 2025 | Jul 30, 2025 | $0.92vs $0.48+91.7% | $157Mvs $142M+11.1% |
Based on last 12 quarters of dataView full earnings history →
TMDX Peer Comparison
TransMedics Group, Inc. (TMDX) competitors in Device suppliers, distribution, and services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AVXL | 252.99M | 2.73 | -5.06 | -38.76% | ||||
 STVN | 4.79B | 17.54 | 31.10 | 3.21% | 11.75% | 9.63% | 0.32 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 LIVN | 4.31B | 78.50 | -17.64 | 10.74% | 7.47% | 9.13% | 0.39 | |
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 | |
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 | |
 MMSI | 4.01B | 67.22 | 31.56 | 11.66% | 9.03% | 8.95% | 0.57 | |
 ITGR | 3.13B | 90.96 | 31.47 | 7.57% | 7.67% | 8.23% | 0.80 |
Compare TMDX vs Peers
TransMedics Group, Inc. (TMDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TMDX Income Statement
TransMedics Group, Inc. (TMDX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 7.68M | 13.02M | 23.6M | 25.64M | 30.26M | 93.46M | 241.62M | 441.54M | 605.49M | 635.89M |
Revenue Growth % | 23.77% | 69.38% | 81.33% | 8.62% | 18.03% | 208.83% | 158.53% | 82.74% | 37.13% | 30.24% |
Cost of Goods Sold | 5.55M | 7.28M | 9.74M | 9M | 9.1M | 28.19M | 87.53M | 179.46M | 242.69M | 260.15M |
COGS % of Revenue | 72.19% | 55.95% | 41.27% | 35.12% | 30.08% | 30.16% | 36.23% | 40.64% | 40.08% | - |
Gross Profit | 2.14M▲ 0% | 5.73M▲ 168.3% | 13.86M▲ 141.8% | 16.64M▲ 20.0% | 21.16M▲ 27.2% | 65.27M▲ 208.5% | 154.09M▲ 136.1% | 262.08M▲ 70.1% | 362.81M▲ 38.4% | 375.74M▲ 0% |
Gross Margin % | 27.81% | 44.05% | 58.73% | 64.88% | 69.92% | 69.84% | 63.77% | 59.36% | 59.92% | 59.09% |
Gross Profit Growth % | 178.98% | 168.32% | 141.77% | 20% | 27.2% | 208.48% | 136.08% | 70.08% | 38.43% | - |
Operating Expenses | 22.56M | 25.97M | 43.47M | 43.02M | 60.59M | 96.71M | 182.82M | 224.59M | 254.22M | 281.3M |
OpEx % of Revenue | 293.6% | 199.52% | 184.15% | 167.79% | 200.21% | 103.48% | 75.66% | 50.86% | 41.99% | - |
Selling, General & Admin | 7.61M | 12.31M | 23.6M | 24.19M | 38.28M | 69.9M | 119.55M | 168.62M | 185.17M | 204.53M |
SG&A % of Revenue | 98.97% | 94.61% | 99.97% | 94.34% | 126.51% | 74.79% | 49.48% | 38.19% | 30.58% | - |
Research & Development | 14.96M | 13.66M | 19.87M | 18.83M | 22.3M | 26.81M | 63.27M | 55.97M | 69.06M | 76.77M |
R&D % of Revenue | 194.63% | 104.91% | 84.18% | 73.45% | 73.7% | 28.69% | 26.18% | 12.68% | 11.4% | - |
Other Operating Expenses | 0 | -213K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -20.43M▲ 0% | -20.24M▲ 0.9% | -29.6M▼ 46.3% | -26.38M▲ 10.9% | -39.43M▼ 49.4% | -31.44M▲ 20.3% | -28.73M▲ 8.6% | 37.5M▲ 230.5% | 108.58M▲ 189.6% | 94.44M▲ 0% |
Operating Margin % | -265.79% | -155.47% | -125.42% | -102.91% | -130.29% | -33.64% | -11.89% | 8.49% | 17.93% | 14.85% |
Operating Income Growth % | 11.14% | 0.93% | -46.28% | 10.87% | -49.44% | 20.27% | 8.62% | 230.53% | 189.59% | - |
EBITDA | -19.8M | -19.47M | -28.38M | -24.81M | -37.61M | -27.96M | -20.55M | 57.25M | 135.77M | 115.48M |
EBITDA Margin % | -257.59% | -149.56% | -120.24% | -96.75% | -124.28% | -29.92% | -8.51% | 12.97% | 22.42% | 18.16% |
EBITDA Growth % | 12.25% | 1.66% | -45.78% | 12.59% | -51.61% | 25.66% | 26.5% | 378.61% | 137.13% | 55.83% |
D&A (Non-Cash Add-back) | 630K | 769K | 1.22M | 1.58M | 1.82M | 3.48M | 8.18M | 19.76M | 27.18M | 21.05M |
EBIT | -19.72M | -21M | -29.15M | -24.73M | -40.3M | -32.44M | -15.88M | 50.19M | 121.3M | 104.46M |
Net Interest Income | -524K | -2.42M | -3.56M | -2.33M | -3.87M | -2.83M | 1.71M | -14.41M | -13.78M | -7.82M |
Interest Income | 548K | 0 | 790K | 1.65M | 0 | 900K | 12.5M | 0 | 0 | 2.5M |
Interest Expense | 1.07M | 2.42M | 4.35M | 3.98M | 3.87M | 3.73M | 10.79M | 14.41M | 13.78M | 3.15M |
Other Income/Expense | -365K | -3.48M | -3.9M | -2.33M | -4.75M | -4.73M | 2.06M | -1.72M | -1.06M | -5.11M |
Pretax Income | -20.79M▲ 0% | -23.71M▼ 14.1% | -33.51M▼ 41.3% | -28.72M▲ 14.3% | -44.18M▼ 53.8% | -36.16M▲ 18.1% | -26.67M▲ 26.3% | 35.78M▲ 234.2% | 107.52M▲ 200.5% | 89.33M▲ 0% |
Pretax Margin % | -270.54% | -182.18% | -141.95% | -112% | -145.99% | -38.7% | -11.04% | 8.1% | 17.76% | 14.05% |
Income Tax | 32K | 41K | 40K | 32K | 36K | 66K | -1.64M | 316K | -82.77M | -84.93M |
Effective Tax Rate % | -0.15% | -0.17% | -0.12% | -0.11% | -0.08% | -0.18% | 6.16% | 0.88% | -76.98% | -95.08% |
Net Income | -20.82M▲ 0% | -23.76M▼ 14.1% | -33.55M▼ 41.2% | -28.75M▲ 14.3% | -44.22M▼ 53.8% | -36.23M▲ 18.1% | -25.03M▲ 30.9% | 35.46M▲ 241.7% | 190.29M▲ 436.6% | 171.92M▲ 0% |
Net Margin % | -270.96% | -182.5% | -142.12% | -112.13% | -146.11% | -38.77% | -10.36% | 8.03% | 31.43% | 27.04% |
Net Income Growth % | 13.47% | -14.09% | -41.21% | 14.31% | -53.8% | 18.06% | 30.92% | 241.7% | 436.58% | 251.23% |
Net Income (Continuing) | -20.82M | -23.76M | -33.55M | -28.75M | -44.22M | -36.23M | -25.03M | 35.46M | 190.29M | 171.92M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.44▲ 0% | -1.23▲ 14.6% | -2.36▼ 91.9% | -1.16▲ 50.8% | -1.60▼ 37.9% | -1.23▲ 23.1% | -0.77▲ 37.4% | 1.01▲ 231.2% | 4.87▲ 382.2% | 4.75▲ 0% |
EPS Growth % | 13.25% | 14.58% | -91.87% | 50.85% | -37.93% | 23.13% | 37.4% | 231.17% | 382.18% | 221.32% |
EPS (Basic) | -1.44 | -1.23 | -2.36 | -1.16 | -1.60 | -1.23 | -0.77 | 1.07 | 5.60 | - |
Diluted Shares Outstanding | 14.48M | 19.25M | 14.2M | 24.7M | 27.62M | 29.56M | 32.52M | 35.22M | 40.54M | 36.19M |
Basic Shares Outstanding | 14.48M | 19.25M | 14.2M | 24.7M | 27.62M | 29.56M | 32.52M | 33.23M | 33.99M | 34.38M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TMDX Balance Sheet
TransMedics Group, Inc. (TMDX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 34.04M | 34.79M | 100M | 146.77M | 118.7M | 252.29M | 510.65M | 497.22M | 637.78M | 619.28M |
Cash & Short-Term Investments | 24.66M | 20.24M | 80.69M | 125.64M | 92.45M | 201.18M | 394.81M | 336.65M | 488.37M | 461.74M |
Cash Only | 11.94M | 20.24M | 20.09M | 24.58M | 25.58M | 201.18M | 394.81M | 336.65M | 488.37M | 461.74M |
Short-Term Investments | 12.73M | 0 | 60.6M | 101.06M | 66.87M | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 925K | 3.44M | 6.56M | 6.86M | 5.93M | 27.61M | 63.58M | 97.72M | 84.28M | 90.73M |
Days Sales Outstanding | 43.93 | 96.4 | 101.42 | 97.72 | 71.57 | 107.83 | 96.04 | 80.78 | 50.81 | 51.74 |
Inventory | 7.97M | 9.28M | 11.22M | 11.93M | 14.86M | 20.61M | 44.23M | 46.55M | 48.88M | 49.89M |
Days Inventory Outstanding | 524.41 | 464.93 | 420.27 | 483.77 | 595.8 | 266.82 | 184.46 | 94.69 | 73.52 | 63.89 |
Other Current Assets | 0 | 0 | 1.54M | 2.33M | 5.46M | 2.9M | 8.03M | 16.29M | 16.25M | 16.92M |
Total Non-Current Assets | 2.96M | 7.36M | 5.3M | 5.26M | 16.19M | 24.85M | 195.39M | 306.86M | 430.59M | 815.54M |
Property, Plant & Equipment | 2.46M | 3.47M | 4.79M | 4.75M | 15.69M | 24.35M | 180.49M | 292.45M | 332.81M | 700.97M |
Fixed Asset Turnover | 3.13x | 3.75x | 4.93x | 5.39x | 1.93x | 3.84x | 1.34x | 1.51x | 1.82x | 1.52x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 11.99M | 11.55M | 11.55M | 11.55M |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 2.35M | 2.15M | 1.95M | 0 |
Long-Term Investments | 500K | 500K | 500K | 0 | 500K | 500K | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 6K | 3.39M | 6K | 506K | 0 | 0 | 562K | 708K | 739K | 20.54M |
Total Assets | 37M▲ 0% | 42.16M▲ 13.9% | 105.3M▲ 149.8% | 152.03M▲ 44.4% | 134.89M▼ 11.3% | 277.15M▲ 105.5% | 706.05M▲ 154.8% | 804.08M▲ 13.9% | 1.07B▲ 32.9% | 1.43B▲ 0% |
Asset Turnover | 0.21x | 0.31x | 0.22x | 0.17x | 0.22x | 0.34x | 0.34x | 0.55x | 0.57x | 0.59x |
Asset Growth % | -36.32% | 13.93% | 149.78% | 44.38% | -11.27% | 105.46% | 154.76% | 13.88% | 32.87% | 142.01% |
Total Current Liabilities | 10.9M | 12.55M | 16.11M | 11.88M | 23.24M | 23.66M | 54.93M | 59.91M | 89.31M | 91.92M |
Accounts Payable | 3.52M | 4.72M | 7.25M | 1.21M | 6.65M | 3.34M | 12.72M | 10.29M | 10.35M | 11.15M |
Days Payables Outstanding | 231.25 | 236.55 | 271.55 | 48.89 | 266.68 | 43.26 | 53.03 | 20.93 | 15.57 | 15.15 |
Short-Term Debt | 1.8M | 0 | 0 | 0 | 0 | 0 | 0 | 2.73M | 13.31M | 18.51M |
Deferred Revenue (Current) | 239K | 306K | 166K | 263K | 250K | 241K | 1.96M | 1.74M | 2.9M | 10.72M |
Other Current Liabilities | 569K | 655K | 370K | 6.38M | 11.16M | 8.82M | 17.92M | 45.15M | 62.74M | 59.32M |
Current Ratio | 3.12x | 2.77x | 6.21x | 12.36x | 5.11x | 10.66x | 9.30x | 8.30x | 7.14x | 6.74x |
Quick Ratio | 2.39x | 2.03x | 5.51x | 11.35x | 4.47x | 9.79x | 8.49x | 7.52x | 6.59x | 6.19x |
Cash Conversion Cycle | 337.09 | 324.78 | 250.15 | 532.6 | 400.69 | 331.39 | 227.47 | 154.53 | 108.76 | 100.48 |
Total Non-Current Liabilities | 194.83M | 34.43M | 34.53M | 36.26M | 43.8M | 66.11M | 513.91M | 515.56M | 505.97M | 848.89M |
Long-Term Debt | 6.85M | 33.67M | 34.15M | 34.66M | 35.2M | 58.7M | 506.2M | 509.31M | 456.38M | 800.24M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 8.6M | 7.42M | 7.71M | 6.25M | 0 | 9.34M |
Deferred Tax Liabilities | -1.11M | -759K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 187.98M | 759K | 389K | 1.6M | 0 | 0 | 0 | 0 | 49.59M | 48.65M |
Total Liabilities | 205.72M | 46.98M | 50.65M | 48.13M | 67.04M | 89.77M | 568.85M | 575.47M | 595.27M | 940.81M |
Total Debt | 8.65M | 33.67M | 34.15M | 34.66M | 43.8M | 67.56M | 515.95M | 518.29M | 469.69M | 818.75M |
Net Debt | -3.28M | 13.43M | 14.05M | 10.08M | 18.22M | -133.63M | 121.13M | 181.64M | -18.68M | 357.01M |
Debt / Equity | - | - | 0.62x | 0.33x | 0.65x | 0.36x | 3.76x | 2.27x | 0.99x | 1.66x |
Debt / EBITDA | - | - | - | - | - | - | - | 9.05x | 3.46x | 7.09x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 3.17x | -0.14x | 3.09x |
Interest Coverage | -18.39x | -8.68x | -6.70x | -6.21x | -10.40x | -8.71x | -1.47x | 3.48x | 8.80x | 33.15x |
Total Equity | -168.72M▲ 0% | -4.83M▲ 97.1% | 54.65M▲ 1232.6% | 103.89M▲ 90.1% | 67.85M▼ 34.7% | 187.38M▲ 176.1% | 137.2M▼ 26.8% | 228.6M▲ 66.6% | 473.1M▲ 107.0% | 494.01M▲ 0% |
Equity Growth % | -534.98% | 97.14% | 1232.62% | 90.11% | -34.69% | 176.14% | -26.78% | 66.62% | 106.95% | 329.18% |
Book Value per Share | -11.65 | -0.25 | 3.85 | 4.21 | 2.46 | 6.34 | 4.22 | 6.49 | 11.67 | 13.65 |
Total Shareholders' Equity | -168.72M | -4.83M | 54.65M | 103.89M | 67.85M | 187.38M | 137.2M | 228.6M | 473.1M | 494.01M |
Common Stock | 1K | 331.21M | 424.13M | 502.22M | 510.49M | 666.28M | 641.11M | 697.21M | 750.93M | 764.64M |
Retained Earnings | -312.18M | -335.94M | -369.48M | -398.23M | -442.45M | -478.68M | -503.7M | -468.24M | -277.95M | -270.63M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -149K | -101K | -2K | -95K | -188K | -225K | -199K | -364K | 124K | 2K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TMDX Cash Flow Statement
TransMedics Group, Inc. (TMDX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -23.1M | -25.98M | -32.29M | -30.27M | -28.86M | -45.82M | -13.03M | 48.8M | 192.84M | 220.23M |
Operating CF Margin % | -300.56% | -199.62% | -136.78% | -118.04% | -95.38% | -49.02% | -5.39% | 11.05% | 31.85% | - |
Operating CF Growth % | 4.19% | -12.49% | -24.25% | 6.26% | 4.63% | -58.73% | 71.57% | 474.6% | 295.14% | 2205.66% |
Net Income | -20.82M | -23.76M | -33.55M | -28.75M | -44.22M | -36.23M | -25.03M | 35.46M | 190.29M | 171.92M |
Depreciation & Amortization | 630K | 769K | 1.22M | 1.58M | 1.82M | 3.48M | 8.18M | 19.76M | 27.18M | 32.91M |
Stock-Based Compensation | 70K | 144K | 854K | 2.41M | 6.88M | 10.32M | 19.79M | 33.22M | 36.86M | 37.85M |
Deferred Taxes | -316K | 1.01M | 336K | -431K | 0 | 0 | -1.66M | 0 | -83.54M | -82.48M |
Other Non-Cash Items | 93K | 177K | 475K | 511K | 3.65M | 3.37M | 30.04M | 5.36M | 4.79M | -3.16M |
Working Capital Changes | -2.75M | -4.33M | -1.63M | -5.59M | 3M | -26.76M | -44.35M | -45M | 17.25M | 63.17M |
Change in Receivables | 454K | -2.51M | -3.17M | -218K | 840K | -21.68M | -33.82M | -34.31M | 13.95M | 51.56M |
Change in Inventory | -2.5M | -2.7M | -4.12M | -1.74M | -4.89M | -8.02M | -28.09M | -8.35M | -7.72M | -13.62M |
Change in Payables | -735K | 164K | 3.44M | -5.8M | 5.09M | -3.27M | 6.96M | -1.4M | -19K | 326K |
Cash from Investing | 24.86M | 12.31M | -60.5M | -41.6M | 29.27M | 54.51M | -193.95M | -129.3M | -59.25M | -68.87M |
Capital Expenditures | -263K | -418K | -165K | -455K | -3.52M | -11.91M | -151.85M | 0 | -59.25M | -68.87M |
CapEx % of Revenue | 3.42% | 3.21% | 0.7% | 1.77% | 11.63% | 12.74% | 62.84% | 29.38% | 9.79% | 10.83% |
Acquisitions | 0 | 0 | 60.34M | 41.14M | 0 | 107K | -14.89M | 441K | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 25.12M | 12.72M | -60.34M | -41.14M | 0 | -107K | -27.21M | -129.74M | 0 | 0 |
Cash from Financing | 3K | 22.06M | 92.72M | 75.55M | 1.39M | 167.93M | 400.42M | 22.87M | 16.86M | 17.59M |
Debt Issued (Net) | 0 | 24.36M | 0 | 0 | 0 | 22.46M | 445.38M | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 97.37M | 74.97M | 0 | 139.85M | 0 | 22.87M | -138K | 10.87M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -138K | 1.69M |
Other Financing | 3K | -2.3M | -4.64M | 584K | 1.39M | 5.61M | -44.96M | 0 | 17M | 6.72M |
Net Change in Cash | 2.1M▲ 0% | 8.3M▲ 295.7% | -149K▼ 101.8% | 4.49M▲ 3112.8% | 999K▼ 77.7% | 175.6M▲ 17477.8% | 193.63M▲ 10.3% | -58.16M▼ 130.0% | 151.72M▲ 360.9% | 169.53M▲ 0% |
Free Cash Flow | -23.36M▲ 0% | -26.4M▼ 13.0% | -32.45M▼ 22.9% | -30.72M▲ 5.3% | -32.38M▼ 5.4% | -57.72M▼ 78.3% | -192.09M▼ 232.8% | -80.94M▲ 57.9% | 133.59M▲ 265.0% | 151.36M▲ 0% |
FCF Margin % | -303.98% | -202.83% | -137.48% | -119.82% | -107.01% | -61.76% | -79.5% | -18.33% | 22.06% | 23.8% |
FCF Growth % | 8.7% | -13.02% | -22.91% | 5.33% | -5.41% | -78.25% | -232.77% | 57.86% | 265.04% | 339.39% |
FCF per Share | -1.61 | -1.37 | -2.28 | -1.24 | -1.17 | -1.95 | -5.91 | -2.30 | 3.30 | 4.18 |
FCF Conversion (FCF/Net Income) | 1.11x | 1.09x | 0.96x | 1.05x | 0.65x | 1.26x | 0.52x | 1.38x | 1.01x | 0.88x |
Interest Paid | 0 | 0 | 0 | 0 | 3.33M | 0 | 8.09M | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TMDX Key Ratios
TransMedics Group, Inc. (TMDX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -134.66% | -36.27% | -51.49% | -28.39% | -15.42% | 19.39% | 54.24% | 41.92% |
Return on Invested Capital (ROIC) | - | -176.4% | -57.44% | -21.67% | -29.56% | -33.73% | -13.81% | 8.41% | 18.84% | 13.18% |
Gross Margin | 27.81% | 44.05% | 58.73% | 64.88% | 69.92% | 69.84% | 63.77% | 59.36% | 59.92% | 59.09% |
Net Margin | -270.96% | -182.5% | -142.12% | -112.13% | -146.11% | -38.77% | -10.36% | 8.03% | 31.43% | 27.04% |
Debt / Equity | - | - | 0.62x | 0.33x | 0.65x | 0.36x | 3.76x | 2.27x | 0.99x | 1.66x |
Interest Coverage | -18.39x | -8.68x | -6.70x | -6.21x | -10.40x | -8.71x | -1.47x | 3.48x | 8.80x | 33.15x |
FCF Conversion | 1.11x | 1.09x | 0.96x | 1.05x | 0.65x | 1.26x | 0.52x | 1.38x | 1.01x | 0.88x |
Revenue Growth | 23.77% | 69.38% | 81.33% | 8.62% | 18.03% | 208.83% | 158.53% | 82.74% | 37.13% | 30.24% |
Related:TMDX Dividend History·TMDX Revenue History·TMDX Price History·TMDX P/E History·TMDX Financial Ratios·TMDX Institutional Holders
TMDX SEC Filings & Documents
TransMedics Group, Inc. (TMDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
TMDX Frequently Asked Questions
TransMedics Group, Inc. (TMDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
TransMedics Group, Inc. (TMDX) reported $635.9M in revenue for fiscal year 2025. This represents a 10141% increase from $6.2M in 2016.
TransMedics Group, Inc. (TMDX) grew revenue by 37.1% over the past year. This is strong growth.
Yes, TransMedics Group, Inc. (TMDX) is profitable, generating $171.9M in net income for fiscal year 2025 (31.4% net margin).
Dividend & Returns
TransMedics Group, Inc. (TMDX) has a return on equity (ROE) of 54.2%. This is excellent, indicating efficient use of shareholder capital.
TransMedics Group, Inc. (TMDX) generated $151.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.